Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026 New Orleans, Louisiana
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
October 29, 2026
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.